Edition:
United Kingdom

People: Biogen Inc (BIIB.OQ)

BIIB.OQ on NASDAQ Stock Exchange Global Select Market

231.78USD
17 Jun 2019
Change (% chg)

-- (--)
Prev Close
$231.78
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
793,378
52-wk High
$388.67
52-wk Low
$216.13

Vounatsos, Michel 

Mr. Michel Vounatsos has served as the Chief Executive Officer and Director of Biogen Inc. Prior to that, from April 2016 to December 2016, Mr. Vounatsos served as our Executive Vice President and Chief Commercial Officer. Prior to joining Biogen, Mr. Vounatsos spent 20 years at Merck & Co., Inc. (Merck), a pharmaceutical company, where he most recently served as President, Primary Care, Customer Business Line. In this role, he led Merck’s global primary care business unit, a role which encompassed Merck’s cardiology-metabolic, general medicine, women’s health and biosimilars groups and developed and instituted a strategic framework for enhancing the company’s relationships with key constituents, including the most significant providers, payors and retailers and the world’s largest governments. Mr. Vounatsos previously held leadership positions across Europe and in China for Merck. Prior to that, Mr. Vounatsos held management positions at Ciba-Geigy, a pharmaceutical company.

Basic Compensation

Total Annual Compensation, USD 3,590,380
Restricted Stock Award, USD 9,868,540
Long-Term Incentive Plans, USD --
All Other, USD 205,448
Fiscal Year Total, USD 13,664,400

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --